The United States of America, As Represented by the Secretary, Department of Health and Human Services

The University of New Mexico

Other

Novo Nordisk A/s

Aventis Pharma S.a.

University of North Texas

Musc Foundation for Research Development

American National Red Cross

Quest Diagnostics Investments, Inc.

Alan Thomas Remaley

Bryce Chackerian

Stephen J Demosky

Edward B Neufeld

Fairwell Thomas

Marcelo Amar

John A Stonik

John T Schiller

H Bryan Brewer

Bryan H Brewer

Marcelo J A Amar

Soumitra S Ghosh

Chih-Hung Lo

Anna Wolska

Denis O Sviridov

Phillip C Miller

James D Otvos

Madhav N Devalaraja

Marcele J A Amar

Irina Y Shalaurova

Patrice Denefle

Cendrine Lemoine

Catherine Prades

Steingrimur P Stefansson

Scott Gordon

Nicolas Duverger

Marie-Françoise Rosier-Montus

Andras G Lacko

James M Deleo

Alexandra Fowler

Mark Ruddel

Laurent Naudin

Sylvia Santamarina-Fojo

William S Argraves

Nirupama A Sabnis

Samar Hammad

Maureen Sampson

Lita Freeman

Marcele J Amar

H Brewer

John T Schillerr

Mark E Ruddel

Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as A1AT-peptide-enriched HDL particles, and their use in various therapeutic contexts.

Lipoprotein targeting protease inhibitors and uses

The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.

ApoC-II mimetic peptides

A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.

Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same

An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.

Compositions and methods for reducing serum triglycerides

Described herein are methods and systems for the determination of constituents in biosamples by NMR spectroscopy and more specifically for the determination of lipoprotein constituents LP-X, LP-Y, and LP-Z in blood plasma and serum.

Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopy

Composition comprising PCSK9 peptide conjugated to a Qbeta carrier and methods of using the same

PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same

The present disclosure provides targeted drug delivery vehicle compositions comprising a drug composition and targeted poly-amino-acid subunits, methods of manufacture, and methods of treatment for numerous diseases.

Drug delivery vehicle

Disclosed herein are peptides and peptide analogs with multiple amphipathic &#x3b1;-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway, as well as peptides that activate lipoprotein lipase, and compositions comprising such peptides or combinations thereof. Also provided herein are methods of using multi-domain amphipathic &#x3b1;-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells and activate lipoprotein lipase within cells are also disclosed herein.

Peptides promoting lipid efflux

Disclosed herein are peptides or peptide analogs with multiple amphipathic &#x3b1;-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic &#x3b1;-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.

Multi-domain amphipathic helical peptides and methods of their use

Method of treating or inhibiting inflammation by multi-domain amphipathic helical peptides

Isolated nucleic acid molecule encoding a peptide or peptide analog comprising the SEQ ID No. 3

The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.

Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses

Growing community of inventors

Bethesda, MD, United States of America

Alan Thomas Remaley